Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.

Fiche publication

Date publication

août 2025

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric , Pr PETIT Thierry , Dr FUMET Jean-David

Tous les auteurs :
Chator C, Chevrier M, Frenel JS, Guyon F, Sabatier R, Pomel C, Rouge TM, Pautier P, Gladieff L, Follana P, Colombo PE, Petit T, Guillemet C, Marchal F, Narducci F, Fumet JD, Rodrigues M, Bosquet L, Rouzier R, Ray-Coquard I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40779880

Résumé

Approximately 70 % of patients with epithelial ovarian cancer (EOC) will relapse. Beyond the platinum-free interval (PFI), predictive factors for efficacy of subsequent therapies are poorly understood. We evaluated the impact of the PFI on progression-free survival (PFS), overall survival (OS) and the role of therapies used at relapse.